STOCK TITAN

Virios Therapeutics Inc - VIRI STOCK NEWS

Welcome to our dedicated news page for Virios Therapeutics (Ticker: VIRI), a resource for investors and traders seeking the latest updates and insights on Virios Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Virios Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Virios Therapeutics's position in the market.

Rhea-AI Summary
Virios Therapeutics, Inc. announces a new patent that extends global coverage for their antiviral pipeline, focusing on treating Long-COVID symptoms with a combination of valacyclovir and celecoxib. The company's study shows promising results in reducing fatigue, pain, and anxiety associated with Long-COVID, with further trials ongoing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.45%
Tags
covid-19
-
Rhea-AI Summary
Virios Therapeutics, Inc. (VIRI) announced financial results for Q4 and full year 2023, focusing on developing antiviral therapies for fibromyalgia and Long-COVID. Key highlights include FDA communication on IMC-2 Phase 2, upcoming clinical data on valacyclovir/celecoxib for LC, and Phase 2 program initiation in LC. Financially, R&D expenses decreased significantly, leading to a reduced net loss compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
earnings
-
Rhea-AI Summary
Virios Therapeutics, Inc. (VIRI) issues a Shareholder Letter highlighting progress and key milestones in 2024, including plans for a special shareholder meeting to approve a reverse stock split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
none
Rhea-AI Summary
Virios Therapeutics, Inc. (VIRI) plans to advance IMC-2 as a treatment for Long-COVID symptoms, targeting the initiation of a Phase 2 program in the second half of 2024, with data expected in 2025. The company aims to address the unmet medical need associated with Long-COVID symptoms and is funding a placebo-controlled 12-week study of the valacyclovir/celecoxib combination in up to 60 Long-COVID patients. The company has also received input from the FDA on development requirements and key endpoints associated with advancing IMC-2 into Phase 2 development. Virios is preparing for the initiation of a Phase 2 clinical program and expects to provide an update on potential partnership developments later this quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.32%
Tags
covid-19
-
Rhea-AI Summary
Virios Therapeutics, Inc. (Nasdaq: VIRI) has received feedback from the FDA on advancing IMC-2 as a treatment for Long-COVID (LC) illness. The FDA agreed to use fatigue as the primary endpoint and orthostatic intolerance as a key secondary endpoint to assess the effectiveness of IMC-2. Virios is exploring options to advance the IMC-2 LC Phase 2 research program, with the potential to be one of the first approved treatments specifically for LC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
covid-19
-
Rhea-AI Summary
Virios Therapeutics, Inc. (Nasdaq: VIRI) Announces Q3 Financial Results and Milestones - Virios Therapeutics, a biotech company, reported Q3 financial results and upcoming milestones. Key highlights include FDA guidance for Phase 3 development of IMC-1 to treat fibromyalgia, submission of briefing materials for IMC-2 as a Long-COVID treatment, and filing for new IP protection for IMC-2. The company also expects capital to support operations into Q3 of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.58%
Tags
earnings
Rhea-AI Summary
Virios Therapeutics, Inc. will report its third quarter 2023 financial results on November 13, 2023. The company focuses on developing antiviral therapies for chronic diseases, including fibromyalgia and Long-COVID. A webcast and conference call will be held to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.4%
Tags
conferences earnings
-
Rhea-AI Summary
Virios Therapeutics to present at ThinkEquity Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
conferences
-
Rhea-AI Summary
Virios Therapeutics terminates Sales Agreement, focusing on operational priorities
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
Rhea-AI Summary
Virios Therapeutics to present at SHARE™️ Series Monday Management Update for investors on September 18, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
conferences
Virios Therapeutics Inc

Nasdaq:VIRI

VIRI Rankings

VIRI Stock Data

9.23M
16.68M
9.71%
8.12%
0.88%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Alpharetta

About VIRI

innovative med concepts is an international trade and development company located in 1837 commons north drive, tuscaloosa, al, united states.